Healthcare / BiotechnologyTokyo
$377.00
-8.00 (-2.04%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-689.1M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-70.0%
↓Gross Margin
100.0%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-43.1%
FCF CAGR
—
FCF margin
-1046.6%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $72.2M · net income $-916.3M · FCF $-755.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $72.2M | $72.2M | $80.0M | $69.3M | $391.8M |
| Net Income | $-916.3M | $-916.3M | $-756.5M | $-854.2M | $-331.8M |
| EBITDA | $-909.5M | $-909.5M | $-817.9M | $-888.8M | $-426.2M |
| EPS | -133.92 | -133.92 | -118.21 | -158.46 | -68.33 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 77.4% |
| Operating Margin | -1259.4% | -1259.4% | -1021.9% | -1283.4% | -108.8% |
| Net Margin | -1268.8% | -1268.8% | -945.1% | -1233.4% | -84.7% |
| Balance Sheet | |||||
| Current Ratio | 4.79 | 4.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-755.8M | $-755.8M | $-661.2M | $-689.1M | $15.8M |
| Returns | |||||
| ROE | -70.0% | -70.0% | -35.9% | -42.2% | -11.9% |
| Valuation | |||||
| P/B | 1.97 | 1.97 | 2.60 | 1.92 | 0.79 |
| Growth & Yield | |||||
| Revenue Growth | -9.8% | -9.8% | 15.6% | -82.3% | — |
| EPS Growth | -13.3% | -13.3% | 25.4% | -131.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-55.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-118.21 → -133.92
Residual
-55.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.